 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Research > InterMune, Inc.
 |
InterMune, Inc. |
 |
 |
 |
PROFILE |
 |
Orphan drugs for sick children? InterMune hopes so. The company licenses ACTIMMUNE (interferon gamma-1b) from Connetics, its former parent, for diseases that primarily affect children. It currently markets ACTIMMMUNE for chronic granulomatous disease, an immune system disease, and osteopetrosis, a disease causing abnormal bone growth. The company is testing the drug as a treatment for idiopathic pulmonary fibrosis and drug-resistant tuberculosis. The firm also markets Amphotec, a treatment for the life-threatening fungal infection invasive aspergillosis; InterMune licenses this product from ALZA. InterMune seeks to expand the use of its products and to gain marketing approval in other countries.
COMPETITION |
 |
Biogen, Inc. (BGEN)
SciClone Pharmaceuticals, Inc. (SCLN)
Viragen, Inc. (VRA)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 11.20
1-Yr. Sales Growth: 1,766.7%
Employees: 91
Revenue per employee: $123,076.92
KEY PEOPLE |
 |
W. Scott Harkonen
CEO
Timothy P. Lynch
CFO
CONTACT INFO |
 |
1710 Gilbreth Rd., Ste. 301
Burlingame, CA 94010
US
Phone: 650-409-2020
Fax: 650-259-0774
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |